173 results about "Recurrent major depressive episodes" patented technology

The present invention relates to a method of treating disorders including cognition impairment, generalized anxiety disorder, acute stress disorder, social phobia, simple phobias, pre-menstrual dysphoric disorder, social anxiety disorder, major depressive disorder, eating disorders, obesity, anorexia nervosa, bulimia nervosa, binge eating disorder, substance abuse disorders, chemical dependencies, nicotine addiction, cocaine addiction, alcohol addiction, amphetamine addiction, Lesch-Nyhan syndrome, neurodegenerative diseases, late luteal phase syndrome, narcolepsy, psychiatric symptoms anger, rejection sensitivity, movement disorders, extrapyramidal syndrome, Tic disorder, restless leg syndrome, tardive dyskinesia, sleep related eating disorder, night eating syndrome, stress urinary incontinence, migraine, neuropathic pain, diabetic neuropathy, fibromyalgia syndrome, chronic fatigue syndrome, sexual dysfunction, premature ejaculation, and male impotence. This method involves administering to a patient in need of such treatment a therapeutically effective amount of a disclosed compound. Such compounds are 4-phenyl substituted tetrahydroisoquinolines having the Formula IA, IB, IIA, IIB, IIIA or IIIC as set forth herein.

A method and a system for assessing a condition in a subject. An example of a condition is a Major Depressive Disorder (MDD). The method comprises measuring at least one speech-related variable in a subject; extracting a channel-delay correlation structure of the at least one speech-related variable; and generating an assessment of a condition of the subject, based on the correlation structure of the at least one speech-related variable.

The present invention relates to methods of diagnosing, prognosing or treating diseases or disorders in which elevated levels of Abeta protein, including abeta_1-42 are prevalent. In particular, the present invention relates to methods of diagnosing, prognosing or treating a major or minor depressive episode/disorder attributed to elevated levels of Abeta protein, including abeta_1-42, found particularly in body fluids including whole blood, blood cells, serum, plasma, urine and CSF. The invention also relates to the treatment of these disorders by administering an agent that either prevents production of Abeta, prevents aggregation of Abeta fibrils, or that increases the degradation or clearance of Abeta. In addition, the invention provides a method of treating or preventing a major or minor depressive disorder comprising administering an agent that prevents or interferes with Abeta-induced neurotoxicity. The present invention also relates to pharmaceutical compositions comprising such agents and methods of screening for novel agents.

A system and a method for assessing a condition in a subject. Phones from speech of the subject are recognized, one or more prosodic or speech-excitation-source features of the phones are extracted, and an assessment of a condition of the subject, is generated based on a correlation between the features of the phones and the condition.

The invention provides a pharmaceutical composition of duloxetine or its pharmaceutically equivalent derivatives like salts, isomers, complexes, polymorphs, hydrates or esters thereof and at least one buffering agent. The duloxetine or its pharmaceutically equivalent derivative is present from about 2 mg to approximately 200 mg; and the buffering agent is present in an amount of approximately 0.1 mEq to approximately 2.5 mEq per mg of duloxetine. Also provided is a method for treating of major depressive disorder and or diabetic peripheral neuropathic pain comprising administering to a mammal in need of such treatment a therapeutically effective amount of a composition.

Gene signatures associated with electroconvulsive therapy (ECT) and/or electroconvulsive seizures (ECS) are disclosed. Such "signatures" are useful, e.g., for diagnosing and treating neuropsychiatric disorders such as major depressive disorder (MDD), bipolar affective disorder (BAD) and psychotic depression. Such methods are therefore also provided here. The invention additionally provides screening methods that use gene signatures of the invention to identify new therapeutic compounds for treating these disorders.

The invention relates to vortioxetine hydrobromide and in particular relates to a crystal of 1-[2-(2,4-dimethylphenylthioxo)phenyl] piperazine hydrobromide. The crystal uses Cu-K alpha radiation. In a powder X-ray diffraction pattern shown by a 2theta angle, diffraction peaks exist at about 6.89 degrees, 9.73 degrees, 13.78 degrees and 14.62 degrees. The invention also relates to a preparation method of the crystal and a drug composition containing the compound. The compound shows the serotonin reabsorption inhibitory activity, has activities towards a serotonin receptor 1A (5-HT1A) and a serotonin receptor 3 (5-HT3), can be used for treating CNS (central nervous system)-related diseases, in particular can be used for treating depressive disorder, especially major depressive disorder of adults, and can be also used for treating other CNS-related diseases.

The present invention relates to compositions and methods for determining whether an individual is predisposed to major depressive disorder and/or to bipolar disorder. In particular, the present invention provides genetic markers useful alone or in combination with other genetic markers for the diagnosis, characterization and treatment of major (unipolar) depression and/or bipolar disorder.

The invention provides methods for the treatment of major depressive disorder in male subjects and methods for the treatment of psychiatric disorders at high altitudes by administering one or more creatine-containing compounds.

Depression and bi-polar depression are treated with an acetyl-L-carnitine (ALCAR), thereby avoiding unwanted side-effects exhibited by conventional antidepressant agents. ALCAR also helps prevents recurrent episodes of depression and bi-polar depression and both provides beneficial membrane phospholipid and high-energy phosphate changes in a brain of human subjects with major depressive disorders (MDD).

The present invention relates to the treatment of major depressive disorder (MDD), and the prevention of suicidality associated therewith, using the uncompetitive NMDA receptor antagonist memantine.

Materials and Methods for stratifying disease severity and for monitoring major depressive disorder are provided.

The present invention relates generally to the detection or diagnosis of depressive disorders, and provides methods and compositions useful for this purpose. In particular, the present invention provides biomarkers for the detection or diagnosis of major depressive disorder, and methods of use thereof.

The invention provides an application of a combined drug composition of ketamine or S-(+)-ketamine or a pharmaceutically acceptable salt of ketamine or S-(+)-ketamine, and escitalopram or a pharmaceutically acceptable salt of escitalopram, to the preparation of drugs for treating major depressive disorder. The major depressive disorder can be major depressive disorder breaking out for the first time, major depressive disorder breaking out again or refractory depression. The invention furthermore provides an application of ketamine or S-(+)-ketamine or the pharmaceutically acceptable salt of ketamine or S-(+)-ketamine to the preparation of the drugs for treating the major depressive disorder, and a drug preparation containing ketamine or S-(+)-ketamine or the pharmaceutically acceptable salt of ketamine or S-(+)-ketamine, and escitalopram or the pharmaceutically acceptable salt of escitalopram. Ketamine and conventional antidepressants are used together; and a proper amount of ketamine is intravenously injected once at first day of start of treatment, so that the anti-depression effect of oral antidepressants can be effectively improved, the effect display lag period is remarkably shortened, and suicidal actions of patients can be remarkably reduced.

The present invention relates to a method of treating a central nervous system disorder, such as a mood disorder (e.g., major depressive disorder) or an anxiety disorder (e.g., general anxiety disorder, social anxiety disorder, post traumatic stress disorder, and panic disorder) with a low dose combination of escitalopram and bupropion.

The invention discloses a multimode characteristic information fusing and predicting method of depression suicide behavior. The multimode characteristic information fusing and predicting method comprises the steps of collecting EEG signals, during data collection, using one-sided mastoid as a reference electrode, using opposite side mastoid as a recording electrode, besides, performing three-dimensional psychology pain measurement on testers, and performing neuropsychology behavioral indicator judgment on an simulated balloon risk task; preprocessing data, detecting EEG signal synchronicity onthe preprocessed EEG data through calculating PLV value between brain electrodes, and performing brain network construction through the PLV value; and by a pattern recognition method, performing classification on depression patient samples having high-risk suicide behavior and depression patient samples having low-risk suicide behavior. According to the multimode characteristic information fusingand predicting method disclosed by the invention, classification accuracy can be effectively increased, prediction of high suicide risk of major depressive disorder is objective, and the occurrence of a phenomenon of the suicide behavior is effectively reduced.

Pharmaceutical compositions comprising azelastine or a pharmaceutically acceptable salt of azelastine and alprazolam are disclosed. Methods of using the pharmaceutical compositions for treating patients suffering from one or more psychiatric disorders such as major depressive disorder, generalized anxiety disorder, panic disorder, agitation, social anxiety disorder, mild chronic depression, obsessive-compulsive disorder, premenstrual dysphoric disorder, seasonal affective disorder, dysthymia, childhood enuresis, bipolar disorder, posttraumatic stress disorder, sleep disorder related to anxiety, are also disclosed.

The pharmaceutical composition of the present invention comprises (1) a carbostyril derivative and (2) a serotonin reuptake inhibitor in a pharmaceutically acceptable carrier. The carbostyril derivative may be aripiprazole or a metabolite thereof, which is a dopamine-serotonin system stabilizer. The serotonin reuptake inhibitor may be fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline or escitalopram. The pharmaceutical composition of the present invention is useful for treating patients with mood disorders, particularly depression or major depressive disorder.

The present invention is directed to phenylpiperazine cycloalkanol derivatives, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders, and combinations thereof, particularly those conditions selected from the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy, and combinations thereof.

The present invention is directed to phenylaminopropanol derivatives of formula (I): or a pharmaceutically acceptable salt thereof; wherein: the dotted line between Y and Z represents an optional double bond; the dotted line between the two R4 groups represents an optional heterocyclic ring of 4 to 6 ring atoms that may be formed between the two R4 groups, together with the nitrogen through which they are attached; Y is N, CR6, or C=O; Z is N, CR7, CR5, or C(R5)2; R2 is aryl substituted with 0-3 R1 or heteroaryl substituted with 0-3 R1; R3 is H or C1-C4 alkyl; n is an integer form 0 to 4; x is an integer from 1 to 2; and the other substituents are defined in the claims; compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders, and combinations thereof, particularly those conditions selected form the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy, and combinations thereof.

The present invention relates to an amorphous vortioxetine and salts thereof. In particular, the invention relates to a process for the preparation of an amorphous vortioxetine hydrobromide. Further, the invention also relates to a process for preparation of amorphous vortioxetine free base. The invention also relates to pharmaceutical compositions comprising an amorphous vortioxetine or hydrobromide salt thereof for oral administration for treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD).